Skip to main content

Table 10 Frequency of oncogenic driver mutation in our study cohort

From: Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland

 

Study population (n = 469)

Patients testeda

EGFR

90/469 (19.2)

90/469 (19.2)

KRAS

159/469 (33.9)

159/443 (35.9)

ALK

28/469 (6.0)

28/376 (7.4)

BRAF

12/469 (2.6)

12/309 (3.9)

ERBB2

9/469 (1.9)

9/286 (3.1)

MET

9/469 (1.9)

9/234 (3.8)

PIK3CA

7/469 (1.5)

7/163 (4.3)

RET

4/469 (0.8)

4/208 (1.9)

ROS1

8/469 (1.7)

8/248 (3.2)

  1. Data are absolute number of patients with percentages in parentheses
  2. aPercentages in parentheses refer to the number of tested patients
Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us